A new lab molecule attacks brain tumor cells that resist chemo
Original title: Rewiring mitotic checkpoint control via Mps1 inhibition overcomes DNA repair-mediated resistance in glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on cells in the lab, not in people.
The short version
In lab dishes, a new molecule slowed glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells that shrug off the usual chemo drug.
What was studied. Researchers designed a new small molecule they call G17. They tested it on glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells in lab and cell studies, including cells that resist the chemo drug temozolomide.
What they found. G17 blocks a protein called Mps1. That protein helps cells divide the right way. With it blocked, the tumor cells finished dividing too early and were left with DNA damage. Over time those cells grew poorly. G17 still worked on cells that make MGMT, the enzyme that lets tumors shake off temozolomide.
What this means, and what it doesn't
What it could mean: glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that stops responding to temozolomide is a hard problem. This points to a different way to hit those tumor cells. For now it gives scientists a target worth studying further.
What it doesn't mean: This is not something a patient can get. The work was done on cells in the lab, not in people. G17 has not been tested in any person. It is not a cure, and it may never become a real drug. Most lab findings never get that far.
Source: PubMed, August 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.